Ingenza has successfully applied for EU H2020 SME Instrument funding of €50,000 for Phase 1 of its SYNBIOMAN project, allowing the company to forge ahead with the development of this novel synthetic biology-driven biomanufacturing platform. Successful completion of the Phase 1 study could open the door to additional funding for Phase 2, valued at €2.5 million.
SYNBIOMAN will build on Ingenza’s proprietary industrial synthetic and systems biology tools, helping small and medium-sized biotechnology enterprises to close the gap from lab to market by developing GMP biomanufacturing capabilities that target the production of therapeutic proteins.
Frequently, these drug candidates are sourced from low yielding organisms, have highly complex structures, or are very toxic. As a result, they can be challenging to manufacture, preventing the development of new therapies for currently unmet clinical needs.
Dr David McElroy, Chief Business Officer at Ingenza, said: “We are delighted to have secured EU H2020 SME Instrument support for this project. The Horizon 2020 programme receives thousands of funding applications each year, and fewer than five per cent of applicants are successful. It is a real achievement for our scientific research to be recognised in this way.”